Published in J Clin Invest on May 16, 2016
Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun (2017) 0.76
Autoimmune disease: Reversing systemic lupus erythematosus. Nat Rev Drug Discov (2016) 0.75
Systemic lupus erythematosus: SHP2 inhibition ameliorates disease in lupus-prone mice. Nat Rev Rheumatol (2016) 0.75
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 8.14
Systemic lupus erythematosus. N Engl J Med (2011) 7.79
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci (2003) 6.24
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Crystal structure of the tyrosine phosphatase SHP-2. Cell (1998) 3.48
Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol (2001) 3.30
Pathogenesis of systemic lupus erythematosus. J Clin Pathol (2003) 2.93
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet (2005) 2.75
Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med (1994) 2.71
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem (2005) 2.68
Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest (1998) 2.60
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med (2005) 2.28
Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr (1999) 2.18
Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res (1999) 2.16
The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol (2004) 2.12
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood (2005) 1.96
Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum (2001) 1.84
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum (2000) 1.84
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat (2004) 1.80
Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol (2011) 1.73
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure (1998) 1.67
SLE, atherosclerosis and cardiovascular disease. J Intern Med (2005) 1.66
Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol (1995) 1.62
Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1999) 1.62
Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun (2008) 1.59
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum (2008) 1.59
Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum (2003) 1.56
Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol (2009) 1.52
Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol (2007) 1.51
Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res (2009) 1.49
Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol (1994) 1.40
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene (2001) 1.39
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A (2001) 1.39
Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol (2000) 1.38
Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum (1994) 1.36
Genetic dissection of systemic lupus erythematosus. Curr Opin Immunol (1999) 1.34
Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol (1993) 1.30
Genetic analysis of protein tyrosine phosphatases. Curr Opin Genet Dev (1998) 1.23
Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (2000) 1.21
Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.21
mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med (2010) 1.21
Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun (2006) 1.18
Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction. Mol Cell Biol (1998) 1.17
T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest (2015) 1.17
The regulation of lymphocyte activation by inhibitory receptors. Curr Opin Immunol (2004) 1.12
Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J Immunol (2006) 1.10
Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol (2010) 1.10
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet (2005) 1.09
Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: production of IL-4. Lupus (2002) 1.06
Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J Med Chem (2014) 1.04
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev (2012) 1.03
Key role of ERK pathway signaling in lupus. Autoimmunity (2010) 0.99
Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus. PLoS One (2009) 0.98
IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunol (2014) 0.98
Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. J Immunol (2012) 0.97
The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res (1999) 0.96
T cells and B cells in lupus nephritis. Semin Nephrol (2007) 0.96
Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J Immunol (2012) 0.95
Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling. J Immunol (2001) 0.95
Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus. J Am Soc Nephrol (2005) 0.94
A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clin Immunol (2013) 0.93
Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens (2008) 0.91
77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun (2003) 0.90
Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis. Clin Exp Immunol (2014) 0.89
Linkage at 12q24 with systemic lupus erythematosus (SLE) is established and confirmed in Hispanic and European American families. Am J Hum Genet (2003) 0.89
Noonan syndrome and systemic lupus erythematosus: presentation in childhood. Clin Dysmorphol (2004) 0.85
Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol (2014) 0.85
Programmed cell death 1 and Helios distinguish TCR-αβ+ double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cells. J Immunol (2015) 0.84
The role of T cells in systemic lupus erythematosus: an update. Curr Opin Rheumatol (2014) 0.83
Systemic lupus erythematosus and other autoimmune disorders in children with Noonan syndrome. Am J Med Genet A (2005) 0.83
Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chin Med J (Engl) (2001) 0.83
Systemic lupus erythematosus in a man with Noonan syndrome. Am J Med Genet (2001) 0.83
The unusual association of three autoimmune diseases in a patient with Noonan syndrome. J Adolesc Health (2003) 0.82
Epidemiology: Interpreting studies of interactions between RA risk factors. Nat Rev Rheumatol (2010) 0.81
Increased plasma IL-17F levels in rheumatoid arthritis patients are responsive to methotrexate, anti-TNF, and T cell costimulatory modulation. Inflammation (2015) 0.78
Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice. Br J Pharmacol (2014) 0.78
Noonan syndrome associated with systemic lupus erythematosus. Lupus (2009) 0.77
Noonan syndrome and systemic lupus erythematosus in a patient with a novel KRAS mutation. Clin Exp Rheumatol (2010) 0.76
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Projection of an immunological self shadow within the thymus by the aire protein. Science (2002) 12.15
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A (2004) 3.74
Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol (2008) 3.65
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity (2011) 3.19
Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol Cell (2008) 3.18
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity (2007) 3.02
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell (2004) 2.82
Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab (2006) 2.82
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood (2007) 2.70
Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol (2006) 2.57
Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med (2010) 2.35
Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A (2002) 2.28
Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature (2003) 2.28
SAP couples Fyn to SLAM immune receptors. Nat Cell Biol (2003) 2.27
The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol (2003) 2.26
Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol (2009) 2.21
Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res (2006) 2.17
TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A (2009) 2.13
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci U S A (2007) 2.12
Stops along the RAS pathway in human genetic disease. Nat Med (2006) 2.10
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today (2007) 2.09
Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest (2005) 2.08
VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and PI(3,5)P(2) in yeast and mouse. EMBO J (2008) 2.08
Modifier loci condition autoimmunity provoked by Aire deficiency. J Exp Med (2005) 2.08
The role of IL-23/IL-17 axis in lupus nephritis. J Immunol (2009) 2.06
Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A (2002) 2.04
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 1.98
A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol Cell (2007) 1.98
WAVE2 deficiency reveals distinct roles in embryogenesis and Rac-mediated actin-based motility. EMBO J (2003) 1.98
Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol (2005) 1.98
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A (2008) 1.98
Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med (2011) 1.94
Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J (2009) 1.94
An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med (2006) 1.94
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2009) 1.88
Cutting edge: MyD88 controls phagocyte NADPH oxidase function and killing of gram-negative bacteria. J Immunol (2005) 1.87
TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol (2007) 1.86
Endogenous retroviruses and neighboring genes are coordinately repressed by LSD1/KDM1A. Genes Dev (2011) 1.86
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev (2006) 1.79
Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol (2004) 1.79
Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol (2008) 1.79
The SLAM and SAP gene families control innate and adaptive immune responses. Adv Immunol (2008) 1.79
Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology (2004) 1.78
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res (2008) 1.77
The cell surface receptor SLAM controls T cell and macrophage functions. J Exp Med (2004) 1.77
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol (2007) 1.73
The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J Biol Chem (2002) 1.70
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity (2004) 1.70
Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes (2005) 1.69
SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. Nat Immunol (2010) 1.68
Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol (2005) 1.65
Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PLoS Pathog (2010) 1.65
Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum (2011) 1.65
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem (2006) 1.63
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem (2010) 1.63
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood (2012) 1.63
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 1.63
Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum (2002) 1.62
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood (2012) 1.61
Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol (2008) 1.61
Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell (2007) 1.60
Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling. J Clin Invest (2014) 1.59
Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol (2002) 1.58
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol (2005) 1.58
The SLAM-associated protein signaling pathway is required for development of CD4+ T cells selected by homotypic thymocyte interaction. Immunity (2007) 1.58
Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci U S A (2010) 1.57
The mouse as a model for understanding chronic diseases of aging: the histopathologic basis of aging in inbred mice. Pathobiol Aging Age Relat Dis (2011) 1.56
Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation (2009) 1.56
PAK4 kinase is essential for embryonic viability and for proper neuronal development. Mol Cell Biol (2003) 1.55
Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3. Proc Natl Acad Sci U S A (2006) 1.55
Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol (2010) 1.54
Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol (2009) 1.52
Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest (2005) 1.52
Induction of PP2A Bβ, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proc Natl Acad Sci U S A (2011) 1.49
Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med (2012) 1.49
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov (2011) 1.46